Transdermal THC:CBD:CBN in peripheral diabetic neuropathy: phase III RCT

Introduction and clinical context

The study Transdermal THC:CBD:CBN in peripheral diabetic neuropathy: phase III RCT (PMC · 2024) is part of the scientific research on the use of cannabinoids in diabetic neuropathy.

Peripheral diabetic neuropathy, a common complication of diabetes, presents with neuropathic pain that is hard to control. Trials with inhaled cannabis and with transdermal formulations (THC:CBD:CBN) investigate pain relief, with reports of a dose-dependent effect in some studies. As with other neuropathic pain, use is individualized and integrates into glycemic control and clinical treatment.

Understanding what science shows about the use of cannabinoids in diabetic neuropathy helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Phase III, double-blind RCT (100 participants): transdermal THC:CBD:CBN formula in pain management. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In diabetic neuropathy, cannabinoids modulate neuropathic pain through the endocannabinoid system in the pain-transmission pathways, with inhaled or transdermal formulations (THC:CBD:CBN) seeking a local and systemic effect. Safety considers the diabetic patient, often with cardiovascular and renal comorbidities: dizziness, drowsiness and interactions deserve attention, and THC can have a dose-dependent psychoactive effect. Use integrates into glycemic control and pain treatment, with gradual titration and follow-up, without replacing diabetes-control measures.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PMC · 2024). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help in diabetic neuropathy?

Trials report pain relief (sometimes dose-dependent); use is individualized and integrated into treatment.

Is there a transdermal formulation?

Yes, there are studies with transdermal THC:CBD:CBN formulas for pain management.